Search results for "TRANSPLANTATION"

showing 10 items of 2019 documents

Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

2020

A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs …

0301 basic medicinefunction recoverymedicine.medical_specialtyPopulationimmunomodulationGastroenterologyPathology and Forensic MedicineImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicinecell transplantationAdverse effecteducationSettore MED/04 - Patologia Generalemesenchymal stem cellseducation.field_of_studybusiness.industryMesenchymal stem cellCOVID-19Cell Biologymedicine.diseaseFunction recoveryACE2 negativeTransplantationPneumonia030104 developmental biologyMesenchymal stem cellsNeurology (clinical)Cell transplantationGeriatrics and GerontologybusinessCytokine storm030217 neurology & neurosurgeryCD8Aging and disease
researchProduct

Mitochondrial targeting as a novel therapy for stroke

2018

Stroke is a main cause of mortality and morbidity worldwide. Despite the increasing development of innovative treatments for stroke, most are unsuccessful in clinical trials. In recent years, an encouraging strategy for stroke therapy has been identified in stem cells transplantation. In particular, grafting cells and their secretion products are leading with functional recovery in stroke patients by promoting the growth and function of the neurovascular unit – a communication framework between neurons, their supply microvessels along with glial cells – underlying stroke pathology and recovery. Mitochondrial dysfunction has been recently recognized as a hallmark in ischemia/reperfusion neur…

0301 basic medicinelcsh:Diseases of the circulatory (Cardiovascular) systemAginglcsh:Medical technologyimpaired mitochondriavasculatureBioenergeticmedicine.medical_treatmentClinical Trials and Supportive ActivitiesIschemiaregenerative medicineReview ArticleBioenergeticsMitochondrionblood–brain barrierBioinformaticsstem cell therapycerebral ischemiaCell therapy03 medical and health sciences0302 clinical medicineClinical Researchmedicineneurovascular unitStrokeTransplantationbusiness.industryNeurosciencesGeneral MedicineStem-cell therapyblood-brain barrierStem Cell Researchmedicine.diseaseendothelial cellsBrain DisordersReview articleStrokeTransplantationtransfer of healthy mitochondria030104 developmental biologylcsh:R855-855.5lcsh:RC666-701endothelial cellStem cellbusiness030217 neurology & neurosurgeryBrain Circulation
researchProduct

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

2018

Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of Vγ9Vδ2 T cells in vitro. However, this inclination is often lost in vivo due to multiple mechanisms mediated by tumor cells and local microenvironment. Multiple myeloma (MM) is a paradigm disease in which antitumor immunity is selectively impaired at the tumor site. By interrogating the immune reactivity of bone marrow (BM) Vγ9Vδ2 T cells to phosphoantigens, we have revealed a very early and long-lasting impairment of Vγ9Vδ2 T-cell immune functions which is already detectable in monoclonal gammopathy of undetermined …

0301 basic medicinelcsh:Immunologic diseases. AllergyStromal cellbone marrowMini ReviewImmunologyVγ9Vδ2 T cells immune checkpoints multiple myeloma immune suppression bone marrow03 medical and health sciences0302 clinical medicineImmune systemAutologous stem-cell transplantationmedicineImmunology and AllergyMultiple myelomabusiness.industryimmune checkpointsmedicine.diseaseVγ9Vδ2 T cellsIn vitromultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer cellCancer researchBone marrowimmune suppressionbusinesslcsh:RC581-607Monoclonal gammopathy of undetermined significanceFrontiers in Immunology
researchProduct

Interleukin-22 in Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

2016

International audience; Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is still limited by complications, such as graft-versus-host disease (GVHD), which is associated with important morbidity and mortality. Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells. Recently, the contribution of innate immunity in GVHD triggering has been investigated by several groups and resulted in …

0301 basic medicinelcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/Immunologyalloreactivitymedicine.medical_treatmentImmunologyInflammationchemical and pharmacologic phenomenaHematopoietic stem cell transplantationReviewBiologyInterleukin 2203 medical and health sciencesgraft-versus-host-disease0302 clinical medicineImmune systemimmune system diseasesallogeneic stem cell transplantationmedicinegraft-versus-host diseaseImmunology and AllergyInflammationInnate immune systeminterleukin-22medicine.disease3. Good healthTransplantation030104 developmental biologyGraft-versus-host diseasesurgical procedures operativeImmunology[SDV.IMM]Life Sciences [q-bio]/Immunologymedicine.symptomStem celllcsh:RC581-607030215 immunology
researchProduct

In Vivo Articular Cartilage Regeneration Using Human Dental Pulp Stem Cells Cultured in an Alginate Scaffold: A Preliminary Study

2017

Osteoarthritis is an inflammatory disease in which all joint-related elements, articular cartilage in particular, are affected. The poor regeneration capacity of this tissue together with the lack of pharmacological treatment has led to the development of regenerative medicine methodologies including microfracture and autologous chondrocyte implantation (ACI). The effectiveness of ACI has been shown in vitro and in vivo, but the use of other cell types, including bone marrow and adipose-derived mesenchymal stem cells, is necessary because of the poor proliferation rate of isolated articular chondrocytes. In this investigation, we assessed the chondrogenic ability of human dental pulp stem c…

0301 basic medicinelcsh:Internal medicineArticle SubjectChemistryCartilageRegeneration (biology)0206 medical engineeringMesenchymal stem cell02 engineering and technologyCell BiologyAnatomyChondrogenesis020601 biomedical engineeringCell biology03 medical and health sciences030104 developmental biologymedicine.anatomical_structureDental pulp stem cellsmedicinelcsh:RC31-1245Autologous chondrocyte implantationMolecular BiologyAggrecanStem cell transplantation for articular cartilage repairResearch ArticleStem Cells International
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

2017

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsClinical Decision-MakingDIRECT ACTING ANTIVIRALSAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansHepatologybusiness.industryIncidencePatient SelectionLiver NeoplasmsHepatitis C ChronicHepatologymedicine.diseaseLiver TransplantationTreatment Outcome030104 developmental biologyHepatocellular carcinomaCancer research030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)

2020

The potential impact of direct-acting antivirals (DAAs) in patients with Barcelona Clinic Liver Cancer (BCLC)-B/C stage hepatocellular carcinoma (HCC) is understudied. Patients with HCC have been systematically excluded from randomised controlled trials evaluating the effectiveness of DAAs. Thus, the benefits of DAAs in patients with HCC are less well defined. The presence of active HCC before the initiation of DAA treatment is reported to be a predictor of DAA failure, and studies in patients without HCC have demonstrated that improvements in cirrhosis complications were lower or absent after DAA failure. Even if viral eradication is achieved using DAAs, reversal of liver function impairme…

0301 basic medicinemedicine.medical_specialtyCirrhosisrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentDecision MakingLiver transplantationAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineMedicineHumansStage (cooking)HCCIntensive care medicineDAANeoplasm StagingAntiviral Agent...Hepatologybusiness.industryLiver NeoplasmsPalliative CareCancerHepatitis C Chronicmedicine.diseaseBCLC Stage030104 developmental biologyBCLC-Dliver functionHepatocellular carcinoma030211 gastroenterology & hepatologyLiver functionbusinessLiver cancerBCLC-BBCLC-CHuman
researchProduct

High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations

2016

International audience; AIMS: Mutations in PRKAG2, the gene encoding for the γ2 subunit of 5'-AMP-activated protein kinase (AMPK), are responsible for an autosomal dominant glycogenosis with a cardiac presentation, associating hypertrophic cardiomyopathy (HCM), ventricular pre-excitation (VPE), and progressive heart block. The aim of this study was to perform a retrospective time-to-event study of the clinical manifestations associated with PRKAG2 mutations.METHODS AND RESULTS: A cohort of 34 patients from 9 families was recruited between 2001 and 2010. DNA were sequenced on all exons and flanking sequences of the PRKAG2 gene using Sanger sequencing. Overall, four families carried the recur…

0301 basic medicinemedicine.medical_specialtyHeart blockCardiomyopathymedicine.medical_treatmentCardiomyopathyDisease030204 cardiovascular system & hematologySudden cardiac deathTime-to-event study03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPhysiology (medical)Internal medicineWolff–Parkinson–WhiteVentricular pre-excitationmedicineHeart transplantationbusiness.industryIncidence (epidemiology)Hypertrophic cardiomyopathy[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasePRKAG23. Good health030104 developmental biologyCohortCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct